AusperBio, a pioneering clinical-stage biopharmaceutical company with a robust presence in both the USA and China, is thrilled to announce the successful closure of a $73 million funding round. This significant capital infusion will accelerate the company’s efforts to revolutionize treatments for chronic hepatitis B through its groundbreaking Med-Oligo™ ASO platform. Focused on advancing oligonucleotide and targeted delivery technologies, AusperBio has leveraged novel insights into antisense oligonucleotide (ASO) design and delivery methods that could substantially enhance the efficacy of existing ASO therapeutics. With the proceeds from this funding, AusperBio plans to advance its clinical programs, pushing forward innovative therapies that address a range of viral infections, metabolic conditions, genetic disorders, and immune diseases. The funding will not only bolster ongoing research but also facilitate the exploration of new therapeutic areas, ultimately aiming to provide transformative health solutions for patients worldwide. AusperBio is uniquely positioned to disrupt the traditional treatment landscape with its modular Med-Oligo™ platform, and this latest investment underscores the confidence that investors have in the potential of its technology to change the lives of thousands suffering from chronic conditions. As the company gears up for its next stages of growth, the focus remains steadfast on delivering cutting-edge medical advancements that promise to reshape the future of biopharmaceutical therapy.
Breaking News: AusperBio Secures $73M in Series B Funding to Revolutionize Oligonucleotide Therapies
Recently funded · $73.0M Series bBiopharmaceutical
Get the full Ausperbio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
